AstraZeneca Company Press-Release

DOI:

https://doi.org/10.21320/
AstraZeneca Company Press-Release  
  1. Available from: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html. Accessed February, 2020.
  2. Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Abstract 31 at: American Society of Hematology 2019 Annual Meeting and Exposition.
  3. US Food and Drug Administration. Project Orbis. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis. Accessed February, 2020.
  4. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(1):1–4. doi: 10.1186/s13045-016-0250-9.
  5. Khan Y, O’Brien S. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. Fut Oncol. 2018;15(6):579–89. doi: 10.2217/fon-2018-0637.
  6. gov. Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL. NCT02475681. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02475681?id=NCT02475681&draw=2&rank=1. Accessed February, 2020.
  7. gov. A Study of Acalabrutinib vs Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL. NCT02970318. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02970318. Accessed February, 2020.
  8. American Cancer Society. Key Statistics for Chronic Lymphocytic Leukemia. Available from: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/key-statistics.html. Accessed February, 2020.

License

Copyright (c) 2020 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.
2020-2

Downloads

Published

01.07.2025

Issue

Vol. 13 No. 2 (2020)
NEWS

How to Cite

AstraZeneca Company Press-Release. Clinical Oncohematology. Basic Research and Clinical Practice. 2025;13(2):231–234. doi:10.21320/.